Temperatures hotter than the center of the sun. Magnetic fields hundreds of thousands of times stronger than the earth’s. Neutrons energetic enough to change the structure of a material entirely.
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
The techniques Theodore Biewer and his colleagues are using to measure whether plasma has the right conditions to create fusion have been around awhile.
As scientists study approaches to best sustain a fusion reactor, a team led by Oak Ridge National Laboratory investigated injecting shattered argon pellets into a super-hot plasma, when needed, to protect the reactor’s interior wall from high-energy runaway electrons.
By automating the production of neptunium oxide-aluminum pellets, Oak Ridge National Laboratory scientists have eliminated a key bottleneck when producing plutonium-238 used by NASA to fuel deep space exploration.
A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
With the production of 50 grams of plutonium-238, researchers at the Department of Energy’s Oak Ridge National Laboratory have restored a U.S. capability dormant for nearly 30 years and set the course to provide power for NASA and other missions. Plutonium-238 pr...